

Statin Therapy for Patients with Diabetes (SPD-E)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS®) helps us measure many aspects of performance. This tip sheet provides key details of statin therapy for patients with diabetes (SPD-E).

What Is the Measure?

The percentage of persons ages 40-75 years old during the measurement period with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and who met the following criteria.

- **Received Statin Therapy:** Persons who were dispensed at least one statin medication of any intensity during the measurement year
- **Statin Adherence 80%:** Persons who remained on a statin medication of any intensity for at least 80% of the treatment period

Exclusions

- Persons in hospice or using hospice services during the measurement period
- Persons receiving palliative care in the measurement period
- Persons who have died during the measurement period
- Persons who received In vitro fertilization, had a diagnosis of pregnancy or were dispensed at least one prescription for clomiphene during the measurement period
- Persons with a diagnosis of End Stage Renal Disease (ESRD) or cirrhosis, or who received dialysis during the measurement period or the year prior to the measurement period
- Persons with myalgia, myositis, myopathy or rhabdomyolysis during the measurement period
- Persons with myalgia or rhabdomyolysis caused by a statin any time during the person's history through the last day of the measurement period
- Persons discharged from an inpatient setting with a myocardial infarction on the discharge claim during the year prior to the measurement period
- Persons with coronary artery bypass graft, percutaneous coronary intervention, or other revascularization procedures in any setting during the year prior to the measurement period
- Persons who had at least two diagnoses of ASCVD on different dates of service during the measurement period or the year prior to the measurement period

Denominator

Received Statin Therapy: Persons who were dispensed at least one statin medication of any intensity during the measurement year

All summaries of the measures contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Florida Blue is an independent licensee of the Blue Cross and Blue Shield Association.

Continued next page

Numerator

Received Station Therapy

- At least one dispensing event for a high-intensity, moderate-intensity or low-intensity statin medication during the measurement period.

Statin adherence 80%

- Proportion of days covered (PDC) of at least 80% during the treatment period

Statin Medications

- | | |
|---------------------------------|--------------------------------|
| • Atorvastatin (+/- amlodipine) | • Rosuvastatin (+/- ezetimibe) |
| • Fluvastatin | • Pitavastatin |
| • Lovastatin | • Simvastatin (+/-ezetimibe) |
| • Pravastatin | |

Best Practices

- Encourage persons to use their Florida Blue card at the pharmacy to generate pharmacy claims and capture person compliance.
- Reinforce the role and importance of statin therapy. Together, identify and resolve person-specific adherence barriers or concerns, such as the health benefits, side effects, cost, and timely refills.
- Statin use should always be accompanied by lifestyle modifications focused on diet and weight loss to improve a patient's lipid panel.

Measure updates will not be reflected in gap closures until the measure requirements are shared in the fall.

Content reproduced with permission from HEDIS® MY2026, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit [NCQA.org/Publications](https://www.ncqa.org/Publications)

Florida Blue is an independent licensee of the Blue Cross and Blue Shield Association.